<DOC>
	<DOCNO>NCT02215616</DOCNO>
	<brief_summary>The primary objective study assess efficacy laquinimod 0.5 , 1.0 , 1.5 mg qd patient HD 12 month treatment use UHDRS-TMS .</brief_summary>
	<brief_title>A Clinical Study Subjects With Huntington 's Disease Assess Efficacy Safety Three Oral Doses Laquinimod</brief_title>
	<detailed_description />
	<mesh_term>Huntington Disease</mesh_term>
	<criteria>Documentation prior positive genetic testing HD , clinical diagnosis symptomatic HD Presence 3649 CAG repeat , inclusive , huntingtin gene base centralize CAG test screen . Male female 2155 year age , inclusive , onset HD 18 year age Women childbearing potential ( woman post menopausal undergone surgical sterilization ) must practice acceptable method birth control 30 day take study treatment , 2 acceptable method birth control study duration 30 day last dose treatment administer . A sum &gt; 5 point UHDRS TMS screen visit Able willing provide write informed consent prior study related procedure perform screening visit . Patients legal guardian consent accord local requirement Willing provide blood sample screen visit Willing able take oral medication able comply study specific procedure Ambulatory , able travel study centre , judge investigator likely able continue travel duration study Availability willingness caregiver , informant , family member provide input study visit . A caregiver recommend someone attend patient least 2 3 time per week least 3 hour per occasion , suitability caregiver judge investigator For patient take allow antidepressant medication , dose medication must keep constant least 30 day baseline must keep constant study Additional criterion may apply , please contact investigator information Use immunosuppressive agent , cytotoxic agent , include cyclophosphamide azatioprine within 12 month prior screen Previous use laquinimod Use moderate/strong inhibitor cytochrome P450 ( CYP ) 3A4 within 2 week prior randomization Use inducer CYP3A4 within 2 week prior randomization Pregnant breastfeeding Subjects clinically significant unstable medical surgical condition may put patient risk participate study may influence result study affect patient 's ability take part study , determine medical history , physical examination , ECG , laboratory test . Such condition may include : A major cardiovascular event ( e.g . myocardial infarction , acute coronary syndrome , decompensated congestive heart failure , pulmonary embolism , coronary revascularization ) occur past 6 month prior randomization Any acute pulmonary disorder A central nervous system ( CNS ) disorder HD may jeopardize subject 's participation study , include disorder demonstrate baseline magnetic resonance imaging ( MRI ) ( base local read ) A gastrointestinal disorder may affect absorption study medication Renal disease Cirrhotic patient moderate severe hepatic impairment Known human immunodeficiency virus ( HIV ) positive status . Patients undergo HIV test screen per local requirement , applicable Any malignancy , exclude basal cell carcinoma , 5 year prior randomization Any clinically significant , abnormal , screen laboratory result opinion investigator , affect patient ' suitability study put patient risk he/she enters study Unsuitable MRI ( e.g , claustrophobia , metal implant ) Alcohol and/or drug abuse within 6 month prior screen , define Diagnostic Statistical Manual Mental Disorders Fourth Edition Text Revision ( DSM IV TR ) criterion substance abuse Patients active suicidal ideation past month measure severe suicide ideation score 4 ( Active Suicidal Ideation Some Intent Act , without Specific Plan ) 5 ( Active Suicidal Ideation Specific Plan Intent ) baseline screen ColumbiaSuicide Severity Rating Scale ( CSSRS ) subject answer `` Yes '' 5 CSSRS Suicidal Behavior Items ( actual attempt , interrupt attempt , abort attempt , preparatory act , behavior ) attempt act perform within 1 year screening , subject , opinion investigator , present serious risk suicide Patients know intracranial neoplasm , vascular malformation , intracranial hemorrhage Known drug hypersensitivity would preclude administration laquinimod placebo , hypersensitivity mannitol , meglumine sodium stearyl fumarate Swallowing difficulty would preclude administration laquinimod placebo capsule Treatment investigational product within 12 week screen patient plan participate another clinical study assess investigational product study . Patients noninterventional and/or observational study exclude participate study Treatment tetrabenazine within 30 day study baseline visit Treatment antipsychotic medication within 30 day study baseline visit Additional criterion may apply , please contact investigator information</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>